Annual report
3034.TEDINET S100OL51
Period2021-04-01 → 2022-03-31
Filed2022-06-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥161.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥165.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥144.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥145.5bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥9.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥7.4bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.4bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.2bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥9.7bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.9bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.1bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.0bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥96.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥100.6bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥102.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥94.2bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥87.3bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥52.1bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥58.7bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥43.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.8bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.0bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥39.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥35.9bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.7bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥19.6bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.8bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥19.8bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥8.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥225m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.7bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.55 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.23 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.73 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥141.19 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥130.19 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,189.7 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,124.31 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,074.57 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,006.55 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥936.74 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.4% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,620 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 5,517 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 5,366 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,070 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 4,678 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥7.0bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.1bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥4.2bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥50.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥105.2bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥5.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.5bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.3bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.7bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥5.5bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.6bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥67.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥63.9bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥57.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥44.0bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥79.7bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥26.5bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥27.7bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥36.2bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥33.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥32.6bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥32.3bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.3bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥146.91 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.45 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.76 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.6 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.97 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥68.2 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥28 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,108.12 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥987.71 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥884.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥846.23 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥841.46 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 38,902,785 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 56 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 49 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 50 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 35 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 3,112 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥80m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥7m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥437m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥437m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥2.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥3.2bn |
| Health Insurance Pharmacyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.1bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.3bn |
| Health Insurance Pharmacyreportable segment | employees | at 2022-03-31 | 4692 pure |
| Health Insurance Pharmacyreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥153.2bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥153.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥59m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2022-03-31 | ¥87.9bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥11.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥223m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥102m |
| Medical Related Businessreportable segment | employees | at 2022-03-31 | 817 pure |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥13.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| Medical Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥377m |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥10.6bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥166.6bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥166.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥437m |
| —segment total | segment assets | at 2022-03-31 | ¥98.5bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥12m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥757m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥757m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥3.7bn |
| Health Insurance Pharmacyreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥2.9bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| Health Insurance Pharmacyreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥148.8bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥148.7bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥55m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2021-03-31 | ¥87.9bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥9.6bn |
| Medical Related Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥407m |
| Medical Related Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥77m |
| Medical Related Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥13.8bn |
| Medical Related Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥13.1bn |
| Medical Related Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥701m |
| Medical Related Businessreportable segment | segment assets | at 2021-03-31 | ¥10.9bn |
| Medical Related Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥3.3bn |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥162.6bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥161.8bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥757m |
| —segment total | segment assets | at 2021-03-31 | ¥98.8bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥11.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,472
| Item | Context | Value | Unit |
|---|---|---|---|
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.159 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.951 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.101 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.857 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.996 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.014 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.415 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.795 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.444 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 4692 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 1877 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03476-000MedicalRelatedBusinessReportableSegmentMember | 817 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03476-000MedicalRelatedBusinessReportableSegmentMember | 219 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 111 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 13 | |
| Number of employees | CurrentYearInstant | 5620 | |
| Average number of temporary workers | CurrentYearInstant | 2109 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 56 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 44.0 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 2.5 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6978000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 1733000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 1450000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 38902785 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 38902785 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 38902785 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 38902785 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 111 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 154 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 29 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 19767 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 20102 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 48866 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 4666 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 116451 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 107627 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 101 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 111114 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 388825 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 20285 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.1256 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0120 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.2994 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |